Following the success of the first iCDP summit last year, we are returning this September to provide the primary industry platform for the advancement of cannabinoid-derived pharmaceuticals. When this summit takes place it will have been just over a year since GW Pharmaceutical’s created the first FDA approved drug containing a cannabinoid API, and several contenders are hot on their heels. However, there are many challenges still obstructing the development of this generation of cannabinoid pharmaceuticals.

Join your peers at the 2nd Annual International Cannabinoid-Derived Pharmaceuticals Summit to solve your challenges in this fast growing field, and to maximise the potential of the next-generation of Cannabinoid pharmaceuticals.

View the event guide to find out more, or click here to register your place.